Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes.
about
HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the StomachPerspectives on new biomarkers in gastric cancer: diagnostic and prognostic applicationsDepth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumabDiscordance rate of HER2 status in primary gastric carcinomas and synchronous lymph node metastases: a multicenter retrospective analysisHER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis.HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis.Expression of human epidermal growth factor receptor 2 in primary and paired parenchymal recurrent and/or metastatic sites of gastric cancer.Comparison of HER2 and Lauren Classification between Biopsy and Surgical Resection Samples, Primary and Metastatic Samples of Gastric Cancer.Discordance Rate of HER2 Status in Primary Gastric Cancer and Synchronous Lymph Node Metastases: Its Impact on Therapeutic Decision and Clinical Management.Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case.HER2 Status in Gastric Cancer: Comparison between Primary and Distant Metastatic Disease.Expression analysis of heat shock protein 90 (HSP90) and Her2 in colon carcinoma.New guidelines for HER2 pathological diagnostics in gastric cancer.Discordant human epidermal growth factor receptor 2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis.Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites.
P2860
Q26780318-FD9DD0D4-E51F-4AC5-97E8-D1286A09CDB9Q27012898-DFE6FDA8-528A-473F-8947-A52774B80A3DQ33761681-9520688D-7E6A-4204-BCFD-FD96C9E5D4A8Q34834419-7D33E569-BA58-4F16-B318-22FF7F97E9FCQ35538755-2812255D-0ABC-4689-8139-DCC9BCEC1E4AQ39080349-848D1309-31F5-4842-9F84-99ED2E0CC942Q39363485-D401CADB-AF8B-4C48-9701-3AAFD5A778C6Q41812451-4E6633A9-2658-4739-973E-53CF6BA32642Q47096927-AC9D1F2F-D015-46AB-8305-108405057E84Q50433440-941FE87C-20EA-4204-9309-6347E8A21957Q50449083-97F609BF-C025-4942-B736-ADBDADCC9C20Q51671698-9BDBAA24-13B1-44A2-B90C-19B7D2BECCAFQ53091400-5CC857DA-FBA9-4F17-8528-B57FFF02221DQ54219250-1B152AD4-E5F8-4805-BD9B-6E699B159984Q54269864-A4143B4A-492A-4DED-A834-9BA5A01241F8Q55066506-F89430AD-0D56-490E-870B-FD3EA4A0CFD6
P2860
Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Differing deregulation of HER2 ...... elated metastatic lymph nodes.
@en
Differing deregulation of HER2 ...... elated metastatic lymph nodes.
@nl
type
label
Differing deregulation of HER2 ...... elated metastatic lymph nodes.
@en
Differing deregulation of HER2 ...... elated metastatic lymph nodes.
@nl
prefLabel
Differing deregulation of HER2 ...... elated metastatic lymph nodes.
@en
Differing deregulation of HER2 ...... elated metastatic lymph nodes.
@nl
P2093
P2860
P356
P1433
P1476
Differing deregulation of HER2 ...... elated metastatic lymph nodes.
@en
P2093
Hidenori Tamegai
Hiroshi Suda
Masashi Fujii
Megumu Watanabe
Mitsugu Kochi
Noriaki Kanamori
Shinobu Masuda
Tadatoshi Takayama
Tomoya Funada
Yoshiaki Mihara
P2860
P2888
P356
10.1186/1746-1596-8-191
P577
2013-11-21T00:00:00Z
P5875
P6179
1001014822